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Supporting Experimental Section  
Purification of Rhodium Metalloinsertor Compounds. The purification of Rh-PPO 
and Rh-PPE was modified from the literature preparations as follows: the crude reaction mixture 
of Rh-PPO or Rh-PPE was loaded onto a C18 SPE cartridge equilibrated with 15% acetonitrile 
in 0.1% TFA(aq). The concentration of acetonitrile was gradually increased and the complex 
eluted from the SPE cartridge with 25% acetonitrile in 0.1% TFA(aq) then dried in vacuo. The 
SPE purified complex was then dissolved in minimal acetonitrile before HPLC purification and 
filtered. Rh-PPO was purified by HPLC using an isocratic method of 75:25 MeCN:H2O + 0.1% 
TFA over 60 min. Rh-PPE was purified by HPLC using  a gradient elution from 85:15 to 5:95 
ACN:H2O + 0.1% TFA over 30 minutes. Peaks corresponding to the desired products were 
verified using ESI-MS and were collected using an automatic fraction collector or by hand. The 
chloride salts were obtained from a Sephadex QAE anion exchange column equilibrated with 
0.1 M MgCl2 and complex structure was verified using NMR.  
Concentration Determination of Rhodium Complexes. A stock solution of each 
rhodium metalloinsertor was made in MilliQ water and a UV-Vis trace was recorded. The 
concentration of stock solution was then determined by using the Cary UV-Vis instrument, as 
well as molar absorptivity values from the literature.21 The following molar absorptivity values 
were used to estimate the concentration of Rh-PPO in water: UV−vis (H2O, pH 7.0): 270 nm 
(122,400 M−1 cm−1), 300 nm (41,600 M−1 cm−1), 430 nm (12,300 M−1 cm−1). The following molar 
absorptivity values were used to estimate the concentration of Rh-PPE in water: UV−vis (H2O, 
pH 7.0): 270 nm (165,800 M−1 cm−1), 300 nm (56,300 M−1 cm−1), 430 nm (16,100 M−1 cm−1).  
Tumor Volume and Final Tumor Weights Analysis for Intratumoral Efficacy 
Experiment. Female NSG mice (28-37 g) were injected subcutaneously with HCT116 cells (2.5 
x 106) suspended in McCoy’s media; 100 μL injections into the right flank. Tumors were allowed 
to grow until they reached ~90 mm3 (11 days). Mice were then randomly assigned to each 
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treatment group with 5 or 10 mice in each, so each group had an average tumor volume of 80-
90 mm3. Mice were assigned to the following treatment groups: saline (n=5) and Rh-PPO at 1 
mpk (n=10). Rh-PPO was dissolved in saline at the MTD (1 mpk) and administered 
intratumorally based on the schedule outlined in Figure 6A. Saline was administered 
intratumorally to the control group based on the same schedule. Mouse body weights and tumor 
volumes were measured twice per week over the course of the study, and tumors were excised 
and weighed on day 18 of the study. Tumor volumes (TV) were estimated by measuring the 
width (W) and length (L) of the tumor using a digital caliper and calculated based on the 
following formula: TV = W2L/2. 
Rh-PPO Continuous Infusion Pharmacokinetic Studies. Initial in vivo studies with 
Rh-PPO utilized Alzet osmotic pumps (Cupertino, CA) to achieve continuous infusion of the 
drug. In these studies, osmotic pumps were filled with Rh-PPO at 1 mpk and implanted 
subcutaneously in four mice. Importantly, Mouse#1 and Mouse#2 received 2 mL, daily, 
subcutaneous infusions of saline for hydration. Mice were assessed for Rh-PPO plasma 
concentration by performing tail vein blood draws every 24 hr. After blood was collected, it was 
immediately transferred to heparinized blood collection vials on ice at time intervals of 24, 48, 
and 72 hr. The blood samples were centrifuged at 15,000 g at RT for 5 min, and the plasma 
supernatant was transferred to 1.5 mL microcentrifuge tubes and maintained at -80oC until 
analysis. Plasma samples were analyzed for Rh-PPO concentration using LC-MS/MS and 
results are displayed in Figure S1.  
LC-MS/MS Analysis of Plasma Samples. Standard Rh-PPO and internal standard 
(INS) Rh-PPE solutions were made as needed and concentration determined via UV-Vis. 
Mouse plasma for preparation of standards and quality controls (QC) were obtained from 
BioChemed Services. LC-MS/MS analysis was performed using a Waters Acquity UPLC system 
(Milford, MA, USA) interfaced with a Waters Quattro Premier XE Mass Spectrometer. HPLC 
separation was achieved using a Luna 3µ  Phenyl-Hexyl 100 x 2 mm column (Phenomenex, 
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Torrance, CA, USA) proceeded by a Phenomenex Phenyl guard column (Torrance, CA, USA). 
The column temperature was maintained at 40°C. The mobile phase consisted of A (0.1% 
formic acid, 10% ACN in water) and B (0.1% formic acid in acetonitrile). The following gradient 
program was used: 0% B (0min, 0.3 ml/min), 8% B (3.2 min, 0.3ml/min), 60% B (4.0 min, 
0.3ml/min), 85% B (5.5 min, 0.3 ml/min), 0% B (5.6 min, 0.3ml/min), 0% B (8.5 min, 0.3ml/min). 
The Total run time was 8.5 minutes. The auto-injector temperature was maintained at 5oC. The 
strong needle wash solution was 0.1% formic acid in 50% ACN and 50% water and the weak 
needle wash solution was 0.1 % formic acid and 10% ACN in water. The electrospray ionization 
source of the mass spectrometer was operated in positive ion mode with a cone gas flow of 25 
L/hr and a desolvation gas flow of 900 L/hr. The capillary voltage was set to 0.7 kV for both Rh-
PPO and INS (Rh-PPE), and the cone voltages were optimized to 45 V for Rh-PPO and 51 V for 
INS, respectively. The collision voltages were set to 48 V for both Rh-PPO and Rh-PPE. The 
source temperature was 125oC and the desolvation temperature was 480°C. A solvent delay 
program was used from 0 to 3.8 minutes and from 5.2 to 8.5 minutes for Rh-PPO and INS, to 
minimize mobile phase to flow to the source. MassLynx version 4.1 software was used for data 












Figure S1. Plasma accumulation of Rh-PPO administered via continuous infusion is 
dependent on mouse hydration. Concentration of Rh-PPO in mouse plasma of NSG mice 
given continuous infusion doses of Rh-PPO at 1 mpk for 72 hr. Importantly, Mouse#1 and 
Mouse#2 received 2 mL, daily, subcutaneous infusions of saline. Amount of intact Rh-PPO 
detected in mouse plasma was analyzed via LC-MS/MS every 24 hrs for 72 hrs total. 































Figure S2. Significant accumulation of rhodium in tumors occurs after intratumoral Rh-
PPO treatment. Rhodium uptake in HCT116 xenograft tumors from Efficacy Experiment # 3 
mice receiving intratumoral injections. Rhodium accumulation in tumors was determined using 
ICP-MS analysis of tumors digested in nitric acid and normalized to initial tumor weight. The 
rhodium concentration of tumors from saline (n=5) and Rh-PPO at 1 mpk (n=10) treated mice 
was averaged with error shown as the standard error of the mean. Statistically significant 
difference between Rh-PPO and saline treatment group tumor rhodium content was found using 



























Datasets S1. In Vivo Tumor Weight Measurements  
 
















Note, blank cells indicate mouse died and tumor weight measurements were not collected.  
Saline i.p. - Tumor 
weight (g)
Rh-PPO 0.5 mpk i.p. - 
Tumor weight (g)
Rh-PPO 1 mpk i.p. - 
Tumor weight (g)
Oxaliplatin 7.5 
mpk i.p. - Tumor 
weight (g)
0.91 0.805 0.872 0.642
0.783 0.574 0.701 0.868




1.424 0.673 0.72 0.706
0.711 0.722 0.631 0.638
0.835 0.538 0.873 0.387
0.677 0.732 0.501 0.675
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Datasets S2. In Vivo Tumor Volume Measurements  














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Intratumoral Tumor Volumes – Raw Data 
 
























































































































































































































































































































































































































































































































































































Datasets S3. Intraperitoneal Mouse Body Weight Measurements  
Intraperitoneal Mouse Body Weights – Raw Data  
 
 
Note, numbers in red with strikethrough represent mice who died during the study.  
 
 
Day 0 Day 3 Day 7 Day 10 Day 14 Day 17 Day 21
Saline Body weight(g) Body weight(g) Body weight(g) Body weight(g) Body weight(g) Body weight(g) Body weight(g)
cage 9- #2 24.6 25.6 24.5 24.8 25.4 25.3 25.3
cage 15- #2 26 27 24.9 25.2 25.1 25.1 24.9
cage 16- #4 25.7 26.3 24 24 24 24 24
cage 2- #2 25 26 25.1 24.6 25.6 27.1 27.2
cage 3- #1 29.1 29.3 28.6 26.9 27.6 27.3 27.7
cage 3- #2 28.5 27.5 27.3 27.4 27.5 27 27.1
cage 3- #3 29.5 30 29.7 28.3 29.1 28.5 28.8
cage 6- #2 28 28.5 27.1 27.7 28.2 28.1 26.4
cage 15- #3 24 25.9 24.5 24.3 24.3 24.2 24.1
cage 16- #1 23.2 24.2 23.9 23.9 24.9 24.6 25.2
Rh-PPO 0.5 mpk
cage 4- #1 26 27.1 27.7 21.8 26.2 25.5 24.7
cage 4- #2 25 25.4 25.4 25.6 24 26.4 24.6
cage 4- #3 26 27.9 26.7 26.8 26.8 27.9 25.5
cage 5- #1 28.8 28 27.9 26.6 27 25 28.6
cage 5- #2 27.4 28.4 26.5 24.5 24.5 24.5 24.5
cage 6- #1 26 25.9 25.8 25 26 25 24.7
cage 6- #3 26 25.1 23.3 24.1 25.6 25.3 25.4
cage 14- #1 27 27.1 26.1 23.9 23.9 25.4 23.2
cage 15- #1 25 25.1 25.3 25.3 24.8 26 25.7
cage 16- #2 26.7 26.3 26.3 27.4 21.7 25.6 26.8
Rh-PPO 1 mpk
cage 7- #1 26.5 26 22.6 22.9 22.8 24.2 21.1
cage 7- #2 26.1 25.2 22.9 23.55 25.4 25 23.5
cage 8- #1 23 22 20.6 20.6 22.4 23.3 20.9
cage 8- #3 22 22.3 21.9 23.2 23.1 23.8 20.9
cage 8- #4 24 21.5 19.3 18.49 18.6 17.9 17.11
cage 9- #3 23.6 24.1 22.5 21.3 21.1 22.4
cage 9- #4 26 24.1 22 23 24.2 24.8 22.9
cage 13- #1 26 25.3 23.4 21 23.8 25.1 26.8
cage 13- #2 26 25 23.6 24.1 24.7 24 24
cage 13- #4 24 23.8 21.9 22.1 24.3 24 25.1
Oxaliplatin 7.5 mpk
cage 10- #1 25 25.6 23.5 24.2 22.7 22.7 23.3
cage 10- #2 25 25.9 24.9 25.6 23.9 24.1 24
cage 10- #3 25 27.1 23.5 24.2 22.9 22.2 21.4
cage 10- #4 27 27.8 25 25 22.4 23 23
cage 11- #1 26 26.5 24.8 24.9 23.3 24.6 22.4
cage 11- #2 25 26.8 24.4 25.1 23.4 23.6 22.4
cage 11- #3 27 27.6 25.4 25.3 22.8 24 24
cage 11- #4 23 24.4 22.1 22.7 22.5 22.3 22.3
cage 12- #1 25 25.2 24.8 25.4 24.1 24.6 23.4
cage 12- #2 24.2 25.8 23.7 24.2 21.4 22.5 22.2
cage 12- #3 25.8 25.9 23.6 23.7 21.9 23 22
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Datasets S4. ICP-MS Metal Content in Tissues and Tumors Data 
 
Rhodium and Platinum Content in Intraperitoneal Treated Tumors – ICP-MS Data  
 
Concentration Rh (ppb) * dilution 
factor/ mg tumor
Concentration Pt (ppb) * dilution 
factor/mg tumor
Vehicle (saline) control  i.p.
cage 1- #1 0.052482784 0.174745509
cage 1- #3 0.022531228 0.042625976
cage 2- #1 0.093664191 0.142277228
cage 2- #3 0.037153341 0.065453461
cage 4- #2 0.109776952 0.089832714
cage 4- #3 0.07568267 0.080070258
cage 1- #2 0.004738574 0.067641682
cage 2- #4 0.006072531 0.024917695
cage 4- #1 0.002875635 0.024974619
Rh-PPO at 0.5 mg/kg i.p.  
cage 5- #3 0.200547143 0.226314286
cage 6- #1 0.322616484 0.056967033
cage 6-#2 0.094322674 0.044488372
cage 6- #3 0.171555707 0.043967391
cage 24- #2 0.208127395 0.062203065
cage 7- #2 0.290863118 0.035437262
cage 8- #2 0.197181122 0.008826531
cage 17- #1 0.079676829 0.016707317
cage 5- #1 0.15257176 0.016688588
cage 5- #2 0.088366085 0.011910224
Rh-PPO at 1 mg/kg i.p.  
cage 8- #3 0.134970226 0.07550308
cage 9- #2 0.234481092 0.075420168
cage 9- #3 0.269531504 0.048313008
cage 11- #1 1.094359375 0.9578125
cage 11- #2 0.244751572 0.058836478
cage 11- #3, 0.406635922 -0.044368932
cage 10- #1 0.301413093 0.043182844
cage 12- #1 0.255026462 0.079610028
cage 23- #2 0.257204013 0.04
Oxaliplatin at 7.5 mg/kg i.p.  
cage 12- #2 0.043661877 3.105823755
cage 12- #3 0.048279592 4.303673469
cage 13- #1 0.03365097 2.330083102
cage 13- #3 0.039495704 3.459725086
cage 14- #4 0.072209424 4.384267016
cage 16- #3 0.075027941 2.091
cage 23- #1 0.048582105 3.251136842
cage 14- #1 0.000952141 5.536246851
cage 14- #2 -0.004772727 2.755787879
cage 14- #3 0.000786585 2.245243902
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Concentration Rh (ppb) * dilution 
factor/ mg tumor
Concentration Pt (ppb) * dilution 
factor/mg tumor
Rh-PPO at 1 mg/kg intratumoral
cage 9- #1 5.922840426 -0.234893617
cage 15- #2 40.83617448 -0.025364583
cage 16- #2 26.32727273 -0.111931818
cage 16- #1 20.53647423 -0.007835052
cage 19- #1 11.42046333 -0.045666667
cage 19- #3 6.354634328 -0.152686567
cage 24- #1 23.76146947 -0.088549618
cage 18- #3 17.11177959 0.020081633
cage 20- #1 26.1112129 0.026064516
Vehicle (saline) control  intratumoral
cage 21- #2 0.158122356 0.016767372
cage 22- #1 0.10492284 0.002098765
cage 22- #2 0.12198419 0.031620553
cage 7- #1 0.033510843 0.018184739
cage 21- #1 0.050166906 0.025956835
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Rhodium and Platinum Content in Intraperitoneal Treated Tissues – ICP-MS Data  
 
Concentration Rh 
(ppb) * dilution 
factor/ mg tumor
Concentration Pt 
(ppb) * dilution 
factor/ mg tumor
Oxaliplatin at 7.5 mg/kg i.p.
10#3 A1 0.17829945 242.919607
10#3 A3 0.094879348 443.0708903
10#3 B 0.008816889 342.7291784
10#3 D1 0.004114044 124.3464885
10#3 D2 -0.025683651 167.3286638
10#3 E1 -0.043280032 224.335784
10#3 E2 0.095076839 78.74368501
10#3 H -0.003543336 12.44292709
10#1 A1 0.126506317 359.0415544
10#1 B 0.101263501 305.633639
10#1 D1 0.017931769 156.7277576
10#1 E1 0.010757841 113.858287
10#1 H 0.014587965 9.335616896
11#4 A1 -0.062400483 601.1345934
11#4 A3 -0.005571233 311.0945959
11#4 B -0.004463519 390.7801062
11#4 D1 -0.031065713 374.4779474
11#4 E1 0.043973111 51.30132232
11#4 E2 -0.004523583 117.5325547
11#4 H 0.083906749 8.812573372
11#2 A1 0.169437977 106.6160663
11#2 A2 0.340750585 118.2702385
11#2 A3 0.062338557 113.899206
11#2 B 0.021722813 141.9773533
11#2 D1 0.015740738 43.02392895
11#2 D2 0.04528978 36.40353381
11#2 E1 0.020061231 21.83394386
11#2 E2 0.023902919 10.90924139




(ppb) * dilution 
factor/ mg tumor
Concentration Pt 
(ppb) * dilution 
factor/ mg tumor
Vehicle (saline) control i.p. 
3#1 A1 1.856486514 19.23619273
3#1 A3 4.799438355 6.295367395
3#1 B 11.36125269 1.995471773
3#1 C 3.013897888 48.94880637
3#1 D 1.447793281 10.59307808
3#1 E 2.120759553 3.704958679
3#1 H 0.065882936 10.77105334
3#1 HAIR 6.354828323 550.5596687
15#3 A1 0.023858391 4.145966125
15#3 A3 0.005993033 12.13183995
15#3 B 0.007557964 1.380781403
15#3 D1 0.25615475 10.46665026
15#3 D2 0.329158836 20.05541704
15#3 E 0.114416615 5.621444823
15#3 H -0.003846825 3.882656789
9#2 A1 1.426893229 17.37924609
9#2 A3 0.137333992 6.08201788
9#2 B 0.051006264 5.492320148
9#2 D1 0.737777879 29.24023824
9#2 D2 0.643142941 23.52012595
9#2 E1 0.805770483 4.413523233
9#2 E2 0.248857236 2.701947997
9#2 H 0.02478345 3.953170803
Rh-PPO at 1 mg/kg i.p.
7#2 A1 38.0914265 5.804048038
7#2 A3 32.73457745 36.58183788
7#2 B 173.9853362 4.028755221
7#2 D 16.15486724 5.166148974
7#2 E 11.00520615 3.098016679
7#2 H 2.153127739 13.35097418
13#2 A1 10.35623497 14.36942475
13#2 A3 38.96588945 4.495299769
13#2 B 176.4218406 2.223283403
13#2 D1 15.02168215 6.548777844
13#2 D2 9.26298776 11.71885114
13#2 E1 13.39236568 7.171561355
13#2 E2 10.2622706 7.635733478
13#2 H 0.296102457 4.256441418
7#1 A1 10.77906918 <0.00
7#1 A3 23.01540005 <0.00
7#1 B 112.8607282 <0.00
7#1 D 18.43725262 <0.00
7#1 E 2.272573512 <0.00
7#1 H 0.127447346 <0.00
 S17 
Letters represent the following tissue code: 
A1/A2/A3.       Spleen, pancreas, kidneys  
B.         Liver  
C.              Heart, skeletal muscle, lungs 
D1/D2.        Small intestine, colon  
E1E2.    Stomach, cecum  
H.       Brain  




























Rh-PPO in Mouse Plasma (Dose 1mg/kg )















Rh-PPO in Mouse Plasma (Dose 0.5 mg/kg )
Sample ID Concentration (uM Rh-PPO)
0.5h-#1 1.069
0.5h-#2 0.267
4h-#1 0.0556
4h-#2 0.127
8h-#1 0.0031
8h-#2 0.0053
